title: The extracellular loop 2 (ECL2) of the human histamine H4 receptor substantially contributes to ligand binding and constitutive activity.
abstract: In contrast to the corresponding mouse and rat orthologs, the human histamine H4 receptor (hH4R) shows extraordinarily high constitutive activity. In the extracellular loop (ECL), replacement of F169 by V as in the mouse H4R significantly reduced constitutive activity. Stabilization of the inactive state was even more pronounced for a double mutant, in which, in addition to F169V, S179 in the ligand binding site was replaced by M. To study the role of the FF motif in ECL2, we generated the hH4R-F168A mutant. The receptor was co-expressed in Sf9 insect cells with the G-protein subunits Gαi2 and Gβ1γ2, and the membranes were studied in [3H]histamine binding and functional [35S]GTPγS assays. The potency of various ligands at the hH4R-F168A mutant decreased compared to the wild-type hH4R, for example by 30- and more than 100-fold in case of the H4R agonist UR-PI376 and histamine, respectively. The high constitutive activity of the hH4R was completely lost in the hH4R-F168A mutant, as reflected by neutral antagonism of thioperamide, a full inverse agonist at the wild-type hH4R. By analogy, JNJ7777120 was a partial inverse agonist at the hH4R, but a partial agonist at the hH4R-F168A mutant, again demonstrating the decrease in constitutive activity due to F168A mutation. Thus, F168 was proven to play a key role not only in ligand binding and potency, but also in the high constitutive activity of the hH4R.
authors: Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry II, University of Regensburg, Regensburg, Germany.
authors: David
authors: D
authors: Wifling
authors: Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry II, University of Regensburg, Regensburg, Germany.
authors: Günther
authors: G
authors: Bernhardt
authors: Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry II, University of Regensburg, Regensburg, Germany.
authors: Stefan
authors: S
authors: Dove
authors: Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry II, University of Regensburg, Regensburg, Germany.
authors: Armin
authors: A
authors: Buschauer
mesh_terms: D001665:Binding Sites; D006632:Histamine / Q000378:metabolism*; D006801:Humans; D008024:Ligands; D008958:Models, Molecular; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism*; D011968:Receptors, Histamine / Q000378:metabolism*; D000074040:Receptors, Histamine H4; D013329:Structure-Activity Relationship
chemical_list: C418607:HRH4 protein, human; D008024:Ligands; D043562:Receptors, G-Protein-Coupled; D011968:Receptors, Histamine; D000074040:Receptors, Histamine H4; D006632:Histamine
references: J Med Chem. 2003 Sep 11;46(19):3957-60
references: 12954048
references: In Silico Pharmacol. 2014 Dec;2(1):1
references: 27502620
references: Trends Pharmacol Sci. 2011 Jan;32(1):35-42
references: 21075459
references: J Med Chem. 2009 Oct 22;52(20):6297-313
references: 19791743
references: Endocrinology. 1997 Jul;138(7):2800-6
references: 9202220
references: Annu Rev Pharmacol Toxicol. 2002;42:437-67
references: 11807179
references: J Med Chem. 2006 Jul 27;49(15):4512-6
references: 16854056
references: Nature. 2011 Jan 13;469(7329):175-80
references: 21228869
references: Trends Pharmacol Sci. 1993 Aug;14(8):303-7
references: 8249148
references: Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
references: 4202581
references: J Biol Chem. 1996 Jan 12;271(2):702-6
references: 8557676
references: J Pharmacol Exp Ther. 2010 May;333(2):382-92
references: 20106995
references: Nature. 2011 Jun 22;475(7354):65-70
references: 21697825
references: Nat Struct Mol Biol. 2005 Apr;12(4):320-6
references: 15768031
references: Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):440-5
references: 14704269
references: Biochemistry. 2009 Feb 17;48(6):1424-38
references: 19166345
references: Br J Pharmacol. 2013 Sep;170(1):101-26
references: 23713847
references: J Pharmacol Exp Ther. 2008 Oct;327(1):88-96
references: 18635748
references: J Biol Chem. 2009 Feb 6;284(6):3529-36
references: 19068482
references: J Med Chem. 2006 Nov 16;49(23):6650-1
references: 17154494
references: J Med Chem. 2009 Apr 23;52(8):2623-7
references: 19317445
references: Naunyn Schmiedebergs Arch Pharmacol. 2011 Sep;384(3):301-17
references: 21800093
references: Mol Pharmacol. 2003 Dec;64(6):1271-6
references: 14645655
references: J Biol Chem. 2007 Mar 9;282(10):7385-96
references: 17213190
references: Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4029-33
references: 8171030
references: Mol Pharmacol. 2010 May;77(5):734-43
references: 20103609
references: Naunyn Schmiedebergs Arch Pharmacol. 2011 May;383(5):457-70
references: 21359967
references: Br J Pharmacol. 2012 Mar;165(6):1688-1703
references: 21864311
references: Nat Struct Mol Biol. 2005 Apr;12(4):287-8
references: 15809647
references: Br J Pharmacol. 2015 Feb;172(3):785-98
references: 24903527
references: J Biol Chem. 1995 Nov 24;270(47):28268-75
references: 7499324
references: Trends Pharmacol Sci. 2013 Jan;34(1):33-58
references: 23254267
references: Nature. 2012 Jan 25;482(7386):547-51
references: 22278061
references: J Biol Chem. 1998 May 1;273(18):5109-16
references: 9556548
references: Mol Pharmacol. 2000 May;57(5):890-8
references: 10779371
references: J Biol Chem. 2007 Aug 31;282(35):25677-86
references: 17591774
references: J Biol Chem. 1994 Mar 4;269(9):6743-52
references: 8120034